Amgen Settles On Bevacizumab And Trastuzumab

Genentech Had Failed To Enjoin Sales Of Biosimilars In US

 
• By Dean Rudge
  
Door
Amgen is now seemingly in the clear for Mvasi and Kanjinti • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Legal & IP

More from Generics Bulletin